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An analysis of carotid artery stenting procedures
performed in New York and Florida (2005-2006):
Procedure indication, stroke rate, and mortality
rate are equivalent for vascular surgeons and non-
vascular surgeons
Robert Steppacher, MD, Nicholas Csikesz, BS, Mohammad Eslami, MD, Elias Arous, MD,
Louis Messina, MD, and Andres Schanzer, MD,Worcester, Mass
Objective:Carotid artery stenting (CAS) has emerged as an alternative to carotid endarterectomy (CEA) for the treatment
of carotid artery stenosis. Unlike CEA, CAS is performed by a wide variety of specialists including vascular surgeons (VS),
interventional cardiologists (IC), and interventional radiologists (IR). This study compares the indications, in-patient
mortality rate, and in-patient stroke rate for patients undergoing CAS, according to operator specialty.
Methods: The State In-patient Databases from New York and Florida, made available by the Healthcare Cost and
Utilization Project, were reviewed by International Classification of Disease (ICD)-9-CM codes to identify all patients
treated with CAS for the years 2005 and 2006. This cohort was then stratified according to operator specialty defined by
procedures performed by each operator over the years surveyed. Primary endpoints were in-patient death and stroke.
Propensity score matching adjusting for indication, demographics, and comorbidities was employed to evaluate the
influence of operator type on outcomes.
Results: During the study period, 4001 CAS procedures were performed. All primary analyses compared VS (n  1350)
to non-VS (n  2651). Patient characteristics were similar, except VS treated fewer patients with CAD (44.2% vs 50.9%,
P < .001) and valvular disease (6.3% vs 8.6%, P  .01) and more patients with chronic lung disease (19.4% vs 15.9%,
P .01). Each group performed an equal proportion of CAS for symptomatic disease (8.1% vs 9.0%, P .32). Univariate
analysis revealed no difference in mortality (0.9% vs 0.5%, P  .13) or stroke (1.3% vs 1.5%, P  .73). Propensity score
matched analysis also demonstrated no difference in mortality (0.7% vs 0.4%, P .48) or stroke (1.1% vs 1.7%, P .27).
Subgroup analysis comparing VS, IC, and IR showed no significant difference in mortality or stroke, but demonstrated
that of the three specialties, IC treated the smallest proportion of symptomatic patients. The proportion of CAS
performed by VS differed significantly by state (New York 46%, Florida 19%, P < .01).
Conclusion:Despite a paucity of level 1 evidence for CAS in asymptomatic patients and current Centers for Medicare and
Medicaid Services (CMS) policy limiting reimbursement for CAS to only high-risk symptomatic patients, VS and non-VS
are treating primarily asymptomatic patients. Perioperative rates of stroke and death are equivalent between VS, IC, and
IR. Regional variation of operator type is substantial, and despite similar outcomes, <50% of CAS is performed by VS.
(J Vasc Surg 2009;49:1379-86.)Since its inception in the early 1990s, carotid artery
stenting (CAS) has emerged as an alternative to carotid
endarterectomy (CEA) for the treatment of carotid artery
occlusive disease. Numerous single institution studies,1
stent registry reports,2,3 administrative dataset evalua-
tions,4-6 and randomized controlled trials,7-9 have assessed
the safety and efficacy of CAS for the treatment of both
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Because the results of these studies have been mixed, CEA,
founded on a history of rigorous evidence-based valida-
tion,11,12 has persisted as the standard of care. Nonetheless,
CAS use has continued to increase dramatically.3
In contrast to CEA, which has been performed uni-
formly by surgeons (primarily those trained specifically in
vascular surgery), CAS has been embraced by multiple
specialty groups that possess catheter and guidewire skills.
Accordingly, professional societies of vascular surgeons,13
cardiologists,14 and interventional radiologists15 have is-
sued consensus statements regarding the indications for use
of this technology and credentialing requirements for pro-
viders performing CAS. Despite the increasing rate of CAS
procedures being performed by these different operators,
the current role of CAS remains undefined. This sentiment
was reinforced by the Centers for Medicare and Medicaid’s
recent decision to deny reimbursement for CAS in any
1379
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defined high risk criteria.16
The purpose of this large administrative dataset study is
to evaluate in-patient mortality and stroke rates for patients
undergoing CAS when stratified according to operator
specialty (vascular surgeons [VS], interventional cardiolo-
gists [IC], and interventional radiologists [IR]). The sec-
ondary goal is to assess for differences in patient character-
istics and procedural indications between the groups of
patients treated by providers from each specialty.
METHODS
Data source. All patients who underwent CAS in the
states of New York (NY) and Florida (FL) during the years
2005-2006 were identified by querying the State In-patient
Databases for the procedure codes 00.63 (carotid artery stent-
ing) and 00.61 (carotid artery angioplasty). These databases
are both supported by the Healthcare Cost and Utilization
Project and contain all patient discharge records from partic-
ipating non-federal academic and private acute care hospitals.
Participation in this program is nearly comprehensive with
218 of 235 eligible hospitals in FL and 206 of 208 eligible
hospitals in NY participating in the years analyzed. The dura-
tion of the study was limited to the years 2005 and 2006 in
order to take advantage of the most recent data available
since the institution of unique International Classification
of Disease (ICD)-9-CM codes (00.63 and 00.61) for
carotid artery stenting and angioplasty. The states of NY
and FL were chosen for analysis as the combined demo-
graphics of these two populous states are thought to be
fairly representative of the United States as a whole.17
Data abstraction. The study cohort consisted of all
patients identified by ICD-9-CM procedural codes 00.63
(carotid artery stenting) and 00.61 (carotid artery angio-
plasty). Demographic variables analyzed included age, gen-
der, payer source, operator volume, resource utilization,
and median income. Comorbidities analyzed included hy-
pertension, complicated and uncomplicated diabetes, renal
failure, valvular disease, congestive heart failure, chronic
lung disease, morbid obesity, and coronary artery disease.
The presence of these comorbidities were identified using
the Elixhauser technique,18 except for coronary artery dis-
ease which was assigned based on the presence of an ICD-9
Table 1. Procedure codes used to categorize operator typ
Vascular surgeon
38.12 – Carotid endarterectomy (open)
38.34 – Aortic resection with anastomosis
38.44 – Aortic resection with replacement
39.29 – Peripheral vascular shunt or bypass
84.15 – Amputation – below the knee
84.17 – Amputation – above the knee
PTCA, Percutaneous transluminal coronary angioplasty.code for angina pectoris, chronic ischemic heart disease, orcardiovascular disease, unspecified. Median income was
determined based on the average census income of the zip
code of the patient’s residence.
Procedure characteristics evaluated included proce-
dural indication (symptomatic vs asymptomatic) and ad-
mission type (elective vs non-elective). Symptom status was
determined according to the method described by McPhee
et al5,19 Any patient with any ICD-9 code for transient
ischemic attack, amaurosis fugax, or stroke at the time of
admission was defined as symptomatic. Admission coding
was used to determine elective vs non-elective admission.
Assignment of operator type and volume. The State
In-patient Databases of NY and FL document a physician
of record for each procedure performed. Each physician
performing any procedure is assigned an anonymous nu-
merical unique provider identifier (UPI). The UPI is pre-
served for every physician for each year of data collected,
and preserved across all hospitals in each state.
The UPI was used to identify all procedures performed
by a specific provider over a given year of the study. Each
CAS practitioner’s annual non-CAS procedure mix was
used to categorize each operator into a given specialty: VS,
IC, or IR. In order to circumvent potential procedural
miscoding in the database, a protocol for the discrimination
of operator specialty type was followed. For each UPI, a
query was performed for ICD-9 codes corresponding to
procedures commonly performed by VS and IC (Table I).
Providers whose UPIs were linked exclusively to ICD-9
codes corresponding to common VS procedures were de-
fined as VS; if linked exclusively to common IC procedures,
providers were defined as IC. Any provider whose UPI was
linked to no common VS or IC procedure was defined
as IR.
Any provider whose UPI was linked to both VS and IC
procedures was assigned as either VS or IC according to the
proportion of VS vs IC codes recorded in the database
(Fig). A threshold of 70% was used for segregation. If
greater than 70% of total recorded procedures were VS
procedures, the provider was assigned to VS; conversely, if
greater than 70% of procedures were IC procedures, the
provider was assigned to IC. All physicians were further
categorized by number of CAS procedures recorded in the
Interventional cardiologist
66 – PTCA
01 – Single vessel PTCA without mention of thrombolytic agent
02 – Single vessel PTCA with mention of thrombolytic agent
05 – Multiple vessel PTCA
06 – Insertion of non-drug-eluting coronary artery stent
07 – Insertion of drug-eluting coronary artery stent
21 – Right heart cardiac catheterization
22 – Left heart cardiac catheterization
23 – Combined right and left heart cardiac catheterizationes
00.
36.
36.
36.
36.
36.
37.
37.
37.database during the study period. Volume categories were
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(9-23 cases/year) and high (23 cases/year).
Endpoints and statistical analysis. The primary
endpoints for this study were in-patient death and
stroke. Death was recorded in the database as a discharge
variable. Stroke was defined in any patient with the
ICD-9 code of 997.02 (postoperative stroke) at the time
of discharge.5
Baseline characteristics and the incidence of death
and stroke were compared between groups using Pear-
son’s 2 analysis for categorical variables and t test for
continuous variables. Comparisons relating to length of
stay were made with the Wilcoxon Rank Sum tests for
non-parametric data. Propensity score matching20 was
employed in order to adjust for different baseline demo-
graphic, comorbid, and procedural covariates. Utilizing
this methodology to control for the aggregate amount of
measured confounding, matched groups of patients un-
dergoing CAS were compared. The covariates included
in the propensity score analysis included age, gender,
race, insurance type, income bracket, comorbidities (hy-
pertension, diabetes, renal failure, valvular heart disease,
congestive heart failure, chronic lung disease, obesity),
admission type (elective vs non-elective), and indication
(symptomatic vs asymptomatic).
All tests were considered statistically significant at an
alpha level of 0.05 (P  .05, two-tailed). All analyses were
Fig. A graphical representation of the method used for the assign-
ment of operator type. Any provider linked to both vascular
surgeons (VS) and interventional cardiologist (IC) codes was
defined as either VS or IC according to the proportion of VS
procedures coded. A threshold of 70% was used for discrimination.
If greater than 70% of total recorded procedures were VS proce-
dures, the provider was assigned to VS; conversely, if greater than
70% of total recorded procedures were IC procedures, the provider
was assigned to IC. Of 645 unique “Unique Provider Identifier”
(UPIs), only four providers were unable to be classified (0.6%). For
clarity, a logarithmic scale is used to display the data.performed using SAS version 9.1 (Cary, NC).RESULTS
During the study period, 4063 CAS procedures were
performed by 645 unique providers. Four providers (62
CAS cases, 1.5% of total) could not be classified according
to the operator type assignment algorithm (described
above) and were, therefore, excluded from all analyses. The
remaining 4001 CAS procedures, performed by 641 oper-
ators, form the study cohort evaluated. Of these, providers
identified as VS performed 1350 of these procedures (VS
group). The remaining 2651 CAS procedures were per-
formed by IC and IR providers (non-VS group). Of these,
1529 CAS procedures were performed by physicians iden-
tified as IC and 1122 by physicians identified as IR.
Patient characteristics (Table II) were similar between
the VS and non-VS groups in terms of age, gender, presen-
tation type, number of comorbidities, and type of comor-
bidities except VS treated fewer patients with CAD (44.2%
vs 50.9%, P .01) and valvular heart disease (6.3% vs 8.6%,
P  .01) and more patients with chronic lung disease
(19.4% vs 15.9%, P  .01). Payer source was similar be-
tween groups. The VS group treated fewer patients with
income $45,000 level (20.2% vs 29%, P  .0005). Each
group performed an equal proportion of CAS procedures
for symptomatic disease (8.1% vs 9.0%, P .32). VS treated
more patients with elective admissions (69.8% vs 66.4%,
P  .03).
CAS procedure volume differed by specialty (Table
III). In the VS group, nearly equal proportions of providers
were classified as low- (33.3%), medium- (35.5%), and
high- (31.2%) volume operators. In contrast, the largest
proportion of IC providers were categorized as high-
volume operators (47.1%), while the largest proportion of
IR providers were categorized as low-volume operators
(45.1%).
Primary endpoints: in-patient stroke and death.
On univariate evaluation, no difference in either mortality
(0.9% vs 0.5%, P  .13) or stroke (1.3% vs 1.5%, P  .73)
between the VS and non-VS groups was observed (Table
IV). No difference in stroke or mortality was seen between
low (9 cases/year), medium (9-23 cases/year), or high
(23 cases/year) volume operators (Table V).
Subgroup analysis by individual specialty was also per-
formed. Direct comparison between the VS and IC groups
and between the VS and IR groups failed to show any
significant difference in the rate of stroke or mortality
(Table VIA). In examining the subset of symptomatic
patients, no difference was seen between the VS and IC
groups and between the VS and IR groups (Table VIB).
After adjusting for potential confounding variables
with the use of propensity score matching, no significant
difference in either stroke or mortality was observed (Table
VII). The mortality rate for patients treated by VS was 0.7%
and by non-VS was 0.4% (P  .48); the stroke rate for
patients treated by VS was 1.1% and by non-VS was 1.7%
(P  .27).
Resource utilization analysis (Table VIII) demon-
strated that the post procedural length of stay was similar
heart
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.13). The VS group had significantly lower total hospital
charges than the non-VS group ($34,800 vs $40,600, P
Table II. Characteristics associated with carotid artery ste
Total
(n  4001)
Carotid stents performed n (%) 100%
Patient characteristics
Mean age, years (median) 71.1
Age 80 years 20.8%
Male (%) 62.0%
Race (%)
White 80.4%
African American 3.3%
Hispanic 7.0%
Other 9.4%
Specific comorbidities:
Hypertension 75.8%
Diabetes mellitus
Uncomplicated 27.9%
Chronic complications 2.5%
Renal failure 6.2%
CAD/MI 48.6%
Valvular disease 7.9%
CHF 8.8%
Chronic lung disease 17.2%
Obesity 3.3%
Number of comorbidities
0 9.4%
1 30.2%
2 29.9%
3 30.5%
Median income by zip code (%)
$1-$24,999 24.4%
$25,000-$34,999 28.4%
$35,000-$44,999 22.6%
$45,000 24.6%
Insurance type (%)
Private/Medicare 93.5%
Medicaid/self pay 4.9%
Presentation type
Asymptomatic (%) 91.3%
Symptomatic (%) 8.7%
TIA (%) 2.6%
Amaurosis fugax (%) 1.2%
Stroke (%) 5.2%
Admission type
Non-elective 32.4%
Elective 67.6%
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive
Table III. Operator type stratified by procedure volume
(TERTILES)
Low volume
(9/years)
Medium volume
(9-23/years)
High volume
(23/years)
Total 34.9% 32.1% 33.0%
VS 33.3% 35.5% 31.2%
IC 28.8% 24.1% 47.1%
IR 45.1% 39.0% 16.0%
VS, Vascular surgeons; IC, interventional cardiologists; IR, interventional
radiologists..0001).In order to assess regional variation in practice patterns,
the frequency with which CAS procedures were performed
by VS and non-VS was compared between the states of NY
and FL. In NY, a significantly greater proportion of CAS
procedures were performed by VS than in FL (45.7% vs
procedures analyzed according to operator specialty
scular surgeon
n  1350)
Non-vascular surgeon
(n  2651) P value
33.7% 66.3%
70.9 (72) 71.2 (72) .27
20.7% 20.9% .84
61.1% 62.5% .39
83.3% 79.0% .001
2.9% 3.5% .33
5.9% 7.5% 0.52
8.0% 10.0% .037
74.7% 76.3% .28
27.3% 28.3% .49
2.0% 2.7% .17
5.5% 6.6% .18
44.2% 50.9% .0001
6.3% 8.6% .01
8.2% 9.1% .30
19.4% 15.9% .25
3.8% 3.1% .25
9.3% 9.4% .86
30.0% 30.0% .83
30.1% 29.8% .88
30.7% 30.4% .86
24.2% 24.5% .84
30.3% 27.3% .14
25.3% 21.1% .025
20.2% 27.0% .005
93.5% 93.5% .99
4.7% 5.0% .66
91.9% 91% .32
8.1% 9.0 .32
2.2% 2.8% .22
1.1% 1.2% .63
5.0% 5.3% .87
30.2% 33.6% .03
69.8% 66.4% .03
failure; TIA, transient ischemic attack.
Table IV. In hospital stroke and mortality comparison
between VS and non-VS
Total
(n  4001)
Vascular
surgeon
(n  1350)
Non-vascular
surgeon
(n  2651) P value
Stroke (%) 1.4% 1.3% 1.5% .73
Mortality (%) 0.6% 0.9% 0.5% .13nting
Va
(18.9%, P  .0001) (Table IX). Of non-VS operators, IC
diolog
adiolo
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state (37.5% vs 39.1% P  .288), but a greater proportion
of CAS procedures was performed by IR in FL than in NY
(42% vs 16.8%, P  .0001).
DISCUSSION
This study demonstrates that CAS is being performed
by multiple specialty groups with equivalent in-hospital
stroke and mortality rates observed between VS and
non-VS operators. This finding, documented on univariate
analysis, was also confirmed using a propensity score
Table V. In hospital stroke and mortality comparison betw
(TERTILES)
Low volume (9/years) M
Non-VS
n  947
VS
n  450
N
n
Stroke (%) 1.8% 1.3% P  .52
Mortality (%) 0.8% 0.7% P  .72
VS, Vascular surgeon; N, number.
Table VI A. In hospital stroke and mortality subgroup an
Total
(n  4001)
Vascular surgeon
(n  1350)
Cardi
(n 
Stroke (%) 1.4% 1.3% 1.
Mortality (%) 0.6% 0.9% 0.
VS, Vascular surgeon; IC, interventional cardiologists; IR, interventional ra
Table VI B. In hospital stroke and mortality subgroup an
Total
(n  348)
Vascular surgeon
(n  109)
Cardio
(n 
Stroke (%) 3.5% 2.8% 3.4
Mortality (%) 4.3% 6.5% 4.6
VS, Vascular surgeons; IC, interventional cardiologists; IR, interventional r
Table VII. In hospital stroke and mortality after
propensity score matching for age, gender, race, primary
insurance, income bracket, comorbidities (hypertension,
uncomplicated diabetes, complicated diabetes, renal
failure, valvular disease, CHF, chronic lung disease,
obesity), admission type, and symptom status
(symptomatic vs asymptomatic)
Propensity score matched cohort
Vascular
surgeon
(n  761)
Non-vascular
surgeon
(n  761) P value
Stroke (%) 1.1% 1.7% .27
Mortality (%) 0.7% 0.4% .48matched analysis to control for multiple confounders. Fur-thermore, on stratified analysis, mortality and stroke rates
were not associated with operator CAS volume and re-
mained equivalent when the VS group was compared indi-
vidually to the IC and IR groups. The other salient finding
in this study is the overwhelming number of asymptomatic
patients treated with CAS (91% of total cohort) by all
operator types.
The rates of in-hospital stroke (1.4%) and mortality
(0.6%) documented in this study is lower than the rate
reported in a recent clinical trial7 and the Society for
Vascular Surgery (SVS) registry.21 However these rates are
comparable to those reported by others using similar ad-
ministrative data5,19,22 and to a recently published large
meta-analysis.4 Because this study was not specifically de-
signed to compare the results of CAS with CEA, we do not
feel it is possible, or appropriate, to make any comments
that would suggest either superiority or inferiority of CAS
over CEA. Furthermore, independent neurologic evalua-
tion was not uniformly utilized in determining the stroke
rate in this administrative dataset. Thus, the stroke rate
reported here cannot and should not be compared to those
reported in prospectively conducted clinical trials.
Medicare has instituted strict guidelines for the reim-
bursement for CAS.16 Currently, under these rules, CAS is
reimbursed by Centers for Medicare and Medicaid Services
(CMS) only in the setting of symptomatic patients who are
deemed “high risk” for CEA according to specific physio-
logic or anatomic parameters. Despite these restrictions,
VS and non-VS stratified by procedure volume
m volume (9-23/years) High volume (23/years)
S
5
VS
n  479
Non-VS
n  899
VS
n  421
1.7% P  .94 1.0% 1.0% P .93
1.0% P  .06 0.3% 1.0% P  .15
s according to specialty
t Interventional radiologist
(n  1122)
P value
(VS vs IC)
P value
(VS vs IR)
2.0% .59 .22
0.5% .24 .18
ists.
according to specialty in symptomatic patients
Interventional radiologist
(n  151)
P value
(VS vs IC)
P value
(VS vs IR)
4.0% .79 .60
2.7% .57 .14
gists.een
ediu
on-V
 80
1.6%
0.3%alysi
ologis
1529)
1%
5%alysis
logist
88)
%
%the majority of patients in the current study were treated
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with previous reports which have evaluated CAS on the
national level using the Nationwide In-patient Sample da-
tabase.McPhee et al reported that for the years 2003-2005,
the proportion of CAS procedures being performed in
asymptomatic patients was 91-92%.5,19
Based on the information available in the State In-
patient Databases studied, it is not possible to comment
specifically on why such a large proportion of asymptomatic
patients are being treated with CAS, nor on how physicians
are being reimbursed for these procedures. The high per-
centage of asymptomatic patients observed in this study
and others may be due to coding errors, leading to misclas-
sification of patients as asymptomatic. However, as hospital
reimbursement (based on diagnosis-related group [DRG]
coding) is much higher for symptomatic than asymptom-
atic patients, it is expected that accurate coding in this area
would be stressed by hospitals. Participation in industry-
sponsored registries (which do reimburse hospitals for CAS
in asymptomatic patients) was not captured in the databases
used for this study and, therefore, cannot be evaluated.
We found that hospital charges for patients treated by
the VS group were significantly lower than for patients
treated by the non-VS group. The statistical significance
observed may be of limited clinical or practical significance.
CAS performed by VS and non-VSwas associated with total
hospital charges of approximately $35,000 and $41,000,
respectively, a fairly small absolute difference in charges.
The average length of stay was equivalent for patients
treated by both groups. The detailed characteristics of
Table VIII. Resource utilization after CAS
Total
(n  4001)
Mean LOS (SD) 3.0  4.7
Median LOS (range) 1 (0-85)
Disposition 85.5%
Home (%) 6.9%
Rehab (%) 0.6%
Died (%) 7.0%
Other (%)
Mean total charges (median) 38,500 (31,400)
LOS, Length of stay; SD, standard deviation; CAS, carotid artery stenting.
Table IX. Frequency of CAS procedures performed in
each state stratified by operator type
New York
(n  2,217)
Florida
(n  1,784) P value
Total 55.4% 44.6% .0001
VS 45.7% 18.9% .0001
IC 37.5% 39.1% .288
IR 16.8% 42.0% .0001
VS, Vascular surgeons; IC, interventional cardiologists; IR, interventional
radiologists; CAS, carotid artery stenting.specific costs for the different operator types would best beevaluated by an in-depth cost analysis. The current dataset
is limited to overall hospital charge information and, there-
fore, specific cost factors attributable directly to the opera-
tor or related complications are unavailable in this type of
study.
On this analysis, it is overwhelmingly clear that the
majority of CAS procedures are being performed by oper-
ators who are not vascular surgeons. When the NY and FL
datasets were analyzed in aggregate, VS performed only
33.7% of all CAS procedures.Moreover, there appears to be
substantial regional variation with regards to the propor-
tion of CAS procedures performed by each operator type.
InNY, VS performed 45.7% of all CAS procedures, whereas
in FL, VS performed only 18.9% of all CAS procedures.
This variation and overall reducedmarket sharemay have to
do with regional referral patterns, different operator thresh-
olds for treatment, and varying appreciation of the evidence
in support of CAS that has been published to date. How-
ever, vascular surgeons remain the only specialists fully
qualified to provide comprehensive treatment of carotid
disease, whether this is provided with a stent or with
endarterectomy. The lower proportion of stents placed by
vascular surgeons may represent more rigorous patient
selection, rather than a lack of endovascular technical
knowledge and ability. This interpretation is supported by
the fact that mortality and stroke rates did not differ be-
tween operator types.
Inherent to this study design are several of the limita-
tions that accompany any work utilizing large administra-
tive datasets. The potential for coding errors relating to
patient factors, hospital characteristics, or outcomes has
previously been described extensively.23 In the context of
this study, the reported stroke rate likely underestimates the
true stroke rate as it was based on the presence or absence of
a single ICD-9-CM code. Furthermore, it is not possible to
determine how many patients were evaluated by an inde-
pendent neurologist as has become the standard in clinical
trials evaluating CAS. Nonetheless, these coding errors are
expected to equally affect patients treated by VS and non-
VS, and, therefore, are unlikely to introduce significant bias
in comparing the outcomes of the different operator types.
Finally, while the primary study outcomes of in-hospital
stroke and mortality are important endpoints, they by no
scular surgeon
n  1350)
Non-vascular surgeon
(n  2651) P value
2.8  4.2 3.0  4.9 .13
1 (0-59) 1 (0-85) .13
84.5% 86.0% .21
7.8% 6.4% .10
0.9% 0.5% .13
6.8% 7.1% .71
400 (28,600) 40,600 (32,300) .0001Va
(
34,means capture all of the elements necessary to judge treat-
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cess employed by the State Inpatient Databases to protect
patient confidentiality precludes the analysis of longitudinal
clinical data. Therefore, it was impossible to evaluate other
equally important outcomes, such as long-term morbidity
and mortality or restenosis.
CONCLUSION
Despite a paucity of evidence in support of performing
CAS in asymptomatic patients and current CMS guidelines
reimbursing CAS for only high-risk symptomatic patients,
both VS and non-VS are treating primarily asymptomatic
patients. Perioperative rates of stroke and death are equiv-
alent between VS, IC, and IR. Regional variation is sub-
stantial, and despite similar outcomes, fewer than 50% of
CAS procedures are performed by VS.
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This study, based on an administrative database of 4000
carotid stent procedures, has three major findings: (1) 91%
of carotid stents are performed in asymptomatic patients, (2)carotid stents (46% by vascular surgeons in New York and only
19% by vascular surgeons in Florida), and (3) early outcomes
across the three specialties performing carotid stenting are
equivalent.
